TABLE 2.

Summary of direct and indirect SIRTI activators with therapeutic potential in tumor occurrence.

Therapy	Cell types	Inhibition of HMGB1	Activated transcription factors	Main outcome	Ref.
Resveratrol	Liver cell	Overexpression and hyperacetylation	SIRT1	Reduce liver damage after liver resection	Yu et al. (2019)
Doxorubicin	Ovarian cancer cell	Expression or acetylation	SIRT1	Suppress migration, invasion or angiogenesis of ovarian cancer cells	Zhu et al. (2017), Jiang W. et al. (2018)
Emodin	Osteosarcoma cell	Acetylation	SIRT1	Alleviate tumour angiogenesis	Qu et al. (2015)